Page 97 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Cripto-1 in cancer diagnosis and therapy

generation antibody therapeutics. Although these findings 5. Conclusion
reinforce the feasibility of antibody-based Cripto-1
inhibition, in vivo efficacy and safety must be thoroughly Cripto-1 has emerged as a promising biomarker with
potential diagnostic and prognostic applications in
evaluated in appropriate animal models and clinical trials.
cancer. Elevated expression levels may aid in risk
Bicyclic peptides, known for their high specificity stratification and inform personalized treatment
and small molecular size, have emerged as promising strategies. However, several challenges hinder its
therapeutic agents. Iaccarino et al. designed a bicyclic clinical translation. Foremost among these is the lack of
69
peptide mimicking the CFC domain of Cripto-1, standardized detection methods. Variability in results
specifically targeting key residues H120 and W123. This obtained from immunohistochemistry, enzyme-linked
peptide exhibited cytotoxic effects against the Cripto-1- immunosorbent assay, and other assays compromises
positive NTERA cancer cell line and blocked Cripto-1- the accuracy, specificity, and reproducibility of Cripto-
mediated intracellular signaling, suggesting potential for 1-based diagnostics. In addition, the occasional low-
therapeutic tumor suppression. In addition, microRNA- level expression of Cripto-1 in normal or non-malignant
based approaches have shown promise in regulating tissues raises concerns about false-positive results,
Cripto-1. For example, miR-3929 downregulated Cripto-1 limiting diagnostic specificity.
by targeting its 3’ UTR in HeLa cervical cancer cells,
whereas miR-3653-3p inhibited papillary thyroid cancer In the context of therapy, Cripto-1 has gained attention
progression through Cripto-1 downregulation. 31,70 These as a molecular target due to its involvement in cell cycle
findings suggest that microRNA-based therapeutics regulation, EMT, and pro-survival signaling pathways.
could offer novel strategies for targeting Cripto-1. Despite Despite encouraging pre-clinical data, no Cripto-1-
promising results in vitro and animal models, the lack of targeted treatment has yet received clinical approval.
clinical validation remains a major limitation for both Major concerns include the potential for off-target effects,
antibody and peptide-based interventions. as Cripto-1 participates in multiple signaling cascades
essential for normal physiological functions. In addition,
The combination with chemotherapy, radiotherapy, and intertumoral and intratumoral heterogeneity poses
novel conjugated drug approaches may further enhance the a significant obstacle to developing broadly effective
treatment efficacy of Cripto-1-targated therapies. A recent therapies.
study demonstrated that a combination of docetaxel with
radiotherapy significantly reduced serum tumor markers To fully realize the clinical potential of Cripto-1,
(CA15-3, CA125, and CEA), as well as Cripto-1, β-catenin, rigorous validation is essential. Future research should
and deletion gene 1 levels in breast cancer patients, leading focus on standardizing detection methods, elucidating
to an improved overall response rate. This combination tissue-specific functions, and mitigating off-target risks.
71
therapy also prolonged median OS, alleviated clinical Large-scale, multi-center clinical trials with long-term
symptoms, and reduced mortality. However, the study follow-up are essential for establishing its clinical utility
was limited by its single-center design and relatively small across diverse cancer types. Addressing these challenges
sample size, underscoring the need for validation through will be critical to unlocking the full potential of Cripto-1
larger, multi-center clinical trials. Although clinical data in oncotherapy, complementing existing approaches in
on Cripto-1-targeted therapies in combination with radiotherapy, chemotherapy, and precision medicine.
radiotherapy or radionuclide-conjugated agents remain Acknowledgments
scarce, accumulating pre-clinical evidence supports their
therapeutic potential. These findings warrant further None.
clinical investigation of Cripto-1 inhibition as a strategy to
enhance cancer treatment outcomes. Funding
Collectively, current studies provide a strong pre- This work was supported by the Science and Technology
clinical rationale for targeting Cripto-1 in cancer therapy. Plan Project of Chengguan District (2022SHFZ0020)
Nonetheless, the absence of large-scale clinical studies and the Key Laboratory of Environmental Ecology
highlights a critical gap. Further in vivo validation and and Population Health in Northwest Minority Areas
translational research are essential to determine the (MWZD202201).
therapeutic viability of Cripto-1-directed strategies and to Conflict of interest
position them within the broader landscape of precision
oncology. The authors declare that they have no competing interests.

Volume 3 Issue 3 (2025) 89 doi: 10.36922/ARNM025130015